

David A Braun

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9356737/publications.pdf>

Version: 2024-02-01

44
papers

3,025
citations

236833

25
h-index

330025

37
g-index

46
all docs

46
docs citations

46
times ranked

3623
citing authors

#	ARTICLE	IF	CITATIONS
1	Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. <i>Nature Medicine</i> , 2020, 26, 909-918.	15.2	488
2	A large peptidome dataset improves HLA class I epitope prediction across most of the human population. <i>Nature Biotechnology</i> , 2020, 38, 199-209.	9.4	324
3	Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma. <i>Cancer Cell</i> , 2021, 39, 649-661.e5.	7.7	263
4	Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. <i>Cancer Cell</i> , 2021, 39, 632-648.e8.	7.7	230
5	Beyond conventional immune-checkpoint inhibition – novel immunotherapies for renal cell carcinoma. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 199-214.	12.5	179
6	Clinical Validation of <i>PBRM1</i> Alterations as a Marker of Immune Checkpoint Inhibitor Response in Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2019, 5, 1631.	3.4	166
7	Metabolomic adaptations and correlates of survival to immune checkpoint blockade. <i>Nature Communications</i> , 2019, 10, 4346.	5.8	139
8	Applying high-dimensional single-cell technologies to the analysis of cancer immunotherapy. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 244-256.	12.5	138
9	Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features. <i>Journal of Clinical Oncology</i> , 2020, 38, 63-70.	0.8	109
10	Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. <i>Nature Communications</i> , 2021, 12, 808.	5.8	84
11	irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial. <i>Clinical Cancer Research</i> , 2019, 25, 2174-2184.	3.2	80
12	Landscape of helper and regulatory antitumour CD4+ T cells in melanoma. <i>Nature</i> , 2022, 605, 532-538.	13.7	70
13	Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE). <i>Journal of Clinical Oncology</i> , 2020, 38, 4240-4248.	0.8	69
14	Effect of Antibiotic Use on Outcomes with Systemic Therapies in Metastatic Renal Cell Carcinoma. <i>European Urology Oncology</i> , 2020, 3, 372-381.	2.6	59
15	HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study. <i>Lancet Oncology</i> , The, 2022, 23, 172-184.	5.1	58
16	Acquired mechanisms of immune escape in cancer following immunotherapy. <i>Genome Medicine</i> , 2018, 10, 87.	3.6	51
17	<i>CDKN2A</i> Alterations and Response to Immunotherapy in Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 4025-4035.	3.2	51
18	PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN. <i>Clinical Cancer Research</i> , 2019, 25, 6080-6088.	3.2	50

#	ARTICLE	IF	CITATIONS
19	Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma. <i>European Journal of Cancer</i> , 2020, 135, 203-210.	1.3	50
20	Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 1371-1380.	3.2	49
21	Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors. <i>Cancer Immunology Research</i> , 2020, 8, 1075-1084.	1.6	47
22	Plasma cell-free DNA variant analysis compared with methylated DNA analysis in renal cell carcinoma. <i>Genetics in Medicine</i> , 2020, 22, 1366-1373.	1.1	40
23	Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2021, 7, 1815.	3.4	40
24	Integrative clinical and molecular characterization of translocation renal cell carcinoma. <i>Cell Reports</i> , 2022, 38, 110190.	2.9	40
25	Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A). <i>Journal of Clinical Oncology</i> , 2022, 40, 2913-2923.	0.8	40
26	Optimized Liquid and Gas Phase Fractionation Increases HLA-Peptidome Coverage for Primary Cell and Tissue Samples. <i>Molecular and Cellular Proteomics</i> , 2021, 20, 100133.	2.5	32
27	From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit. <i>Clinical Cancer Research</i> , 2022, 28, 831-839.	3.2	12
28	Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 4045-4055.	3.2	12
29	Tumor-Infiltrating T Cells – A Portrait. <i>New England Journal of Medicine</i> , 2022, 386, 992-994.	13.9	10
30	Biomarkers of Angiogenesis and Clinical Outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Phase III METEOR Trial. <i>Clinical Cancer Research</i> , 2022, 28, 748-755.	3.2	9
31	Antigen Discovery and Therapeutic Targeting in Hematologic Malignancies. <i>Cancer Journal (Sudbury, Tj ETQq1 1 0,784314 rgBT /Ove</i>	1.0	8
32	State of the Future: Translational Approaches in Renal Cell Carcinoma in the Immunotherapy Era. <i>European Urology Focus</i> , 2020, 6, 37-40.	1.6	6
33	Gene Expression Signature Correlates with Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Everolimus Alone or with a Vascular Disrupting Agent. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1454-1461.	1.9	6
34	Neurotoxicities of novel non-steroidal anti-androgens for prostate cancer: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 166, 103463.	2.0	3
35	Cross-trial validation of molecular subtypes in patients with metastatic clear cell renal cell carcinoma (RCC): The JAVELIN Renal 101 experience.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4531-4531.	0.8	3
36	A Disturbing Decline. <i>New England Journal of Medicine</i> , 2019, 380, 2257-2262.	13.9	2

#	ARTICLE	IF	CITATIONS
37	Real-world progression-free survival (rwPFS) and time to next line of therapy (TTNT) as intermediate endpoints for survival in metastatic breast cancer: A real-world experience.. Journal of Clinical Oncology, 2022, 40, 6520-6520.	0.8	1
38	OTHR-04. INCIDENCE AND SURVIVAL OUTCOMES IN UROTHELIAL CARCINOMA BRAIN METASTASES. Neuro-Oncology Advances, 2019, 1, i18-i19.	0.4	0
39	What was old is new again: learning from the modern master clinician. Clinical Teacher, 2019, 16, 274-276.	0.4	0
40	Effect of high-dose corticosteroid use on efficacy of immune checkpoint inhibitors in patients with renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2021, 39, 4583-4583.	0.8	0
41	Molecular characterization of the tumor microenvironment in chromophobe renal cell carcinoma (ChRCC) and related oncocytic neoplasms.. Journal of Clinical Oncology, 2022, 40, 4549-4549.	0.8	0
42	Dual CDKN2A/MTAP loss compared to CDKN2A loss alone and response to immune-checkpoint inhibitors (ICI) in advanced solid tumors.. Journal of Clinical Oncology, 2022, 40, 2622-2622.	0.8	0
43	Single cell transcriptomic characterization of natural killer (NK) cell populations in clear cell renal cell carcinoma and association with clinical outcomes.. Journal of Clinical Oncology, 2022, 40, e16521-e16521.	0.8	0
44	Fumarate hydratase-deficient renal cell carcinoma: The real-world experience at Dana-Farber Cancer Institute and Moores Cancer Center.. Journal of Clinical Oncology, 2022, 40, e16522-e16522.	0.8	0